After successfully concluding a clinical trial for canine osteosarcoma, ELIAS Animal Health is focused on continuing to push forward in the fight against cancer with a new clinical trial involving combination therapy to treat lymphoma in dogs.
The pilot study, which is currently underway, will evaluate ELIAS Cancer Immunotherapy (ECI®) in combination with VCAA (L- asparaginase, vincristine, cyclophosphamide, and doxorubicin) chemotherapy to treat lymphoma in dogs. All trial participants will be treated at a single investigator site for this preliminary study.
Prevalence of Lymphoma in Dogs
Canine lymphoma is a fairly common type of cancer in dogs. In an article published by VCA Animal Hospitals, authors Malcolm Weir, DVM, MSc, MPH and Catherine Barnette, DVM the disease accounts “for 15-20% of new cancer diagnoses in dogs. It is most common in middle-aged and older dogs, and several breeds are predisposed…”
Overview of the Clinical Trial Protocol for Canine Lymphoma
Patients will first receive eight (8) weekly doses of VCAA chemotherapy to achieve a remission status. Once in remission, patients will receive ECI. Dogs will be monitored for 18 months to assess safety and disease-free intervals. Overall survival time will also be evaluated.
How Will the Study Compare Remission Statuses?
Dogs treated in the clinical trial will be monitored for 18 months and remission statuses will be confirmed upon conclusion of the study. Disease-free intervals determined in the study will be compared to historical data from dogs who were previously and separately treated solely with chemotherapy.
What Is the Goal of This Canine Lymphoma Clinical Trial?
The study will evaluate the safety and preliminary efficacy of administering VCAA chemotherapy followed by ECI to treat canine lymphoma. We are hopeful this combination therapy approach could result in longer remissions and shorter treatment times for dogs diagnosed with lymphoma.